The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

AMD stock has declined in 2026, despite strong revenue growth and accelerating demand for its AI chips. AI infrastructure deals with Meta and OpenAI have improved AMD’s long-term revenue visibility.

Leveraging deep learning for immersive 3D visualization, integrated CT imaging workflows and enhanced precision in lung navigation and surgical planning L&T Technology Services Limited (BSE: 540115, ...

Shares of Advanced Micro Devices (NASDAQ: AMD) are still down by nearly 7.7% so far in 2026 (as of March 12, 2026), even after the company delivered a strong fourth-quarter 2025 performance. AMD ...

Leveraging deep learning for immersive 3D visualization, integrated CT imaging workflows and enhanced precision in lung navigation and surgical planning SAN JOSE ...

This is why MLB teams have analytics departments. Team USA manager Mark DeRosa is coming under fire for saying the Americans already had their quarterfinal spot in the World Baseball Classic secured ...

Team USA opened its game against Italy by resting many of its top starters. Chris Coduto / Getty Images Hours before Tuesday’s stunning and potentially damning upset to Team Italy, in which he did not ...

German Chancellor Friedrich Merz learned the wrong lesson on his recent trip to China. Advanced economies expand and remain competitive not through additional labor inputs but through capital ...

We recently published 17 Stocks Jim Cramer Talked About. Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the stocks that Jim Cramer talked about. Chip designer Advanced Micro Devices, Inc. (NASDAQ ...

Rei Penber is the Deputy Lead Editor for GameRant's Anime and Manga team, originally from Kashmir and currently based in Beirut. He brings seven years of professional experience as a writer and editor ...

California-based biotech Iovance Biotherapeutics announced today that its autologous tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi) led to objective responses in 18 of the 41 patients (44% ...